236 related articles for article (PubMed ID: 34338634)
1. The development of
Ye G; Gallant J; Zheng J; Massey C; Shi K; Tai W; Odle A; Vickers M; Shang J; Wan Y; Du L; Aihara H; Perlman S; LeBeau A; Li F
Elife; 2021 Aug; 10():. PubMed ID: 34338634
[TBL] [Abstract][Full Text] [Related]
2. The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.
Ye G; Gallant JP; Massey C; Shi K; Tai W; Zheng J; Odle AE; Vickers MA; Shang J; Wan Y; Drelich A; Kempaiah KR; Tat V; Perlman S; Du L; Tseng CT; Aihara H; LeBeau AM; Li F
bioRxiv; 2020 Nov; ():. PubMed ID: 33236012
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
Ye G; Pan R; Bu F; Zheng J; Mendoza A; Wen W; Du L; Spiller B; Wadzinski BE; Liu B; Perlman S; Li F
J Virol; 2023 Nov; 97(11):e0144823. PubMed ID: 37855638
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
5. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
6. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L
Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
8. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
9. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
[TBL] [Abstract][Full Text] [Related]
10. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug.
Liu Q; Lu Y; Cai C; Huang Y; Zhou L; Guan Y; Fu S; Lin Y; Yan H; Zhang Z; Li X; Yang X; Yang H; Guo H; Lan K; Chen Y; Hou SC; Xiong Y
Cell Death Dis; 2024 Jun; 15(6):458. PubMed ID: 38937437
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
[TBL] [Abstract][Full Text] [Related]
12. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19.
Esparza TJ; Chen Y; Martin NP; Bielefeldt-Ohmann H; Bowen RA; Tolbert WD; Pazgier M; Brody DL
MAbs; 2022; 14(1):2047144. PubMed ID: 35289719
[TBL] [Abstract][Full Text] [Related]
13. The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization.
Zebardast A; Hosseini P; Hasanzadeh A; Latifi T
Mol Biol Rep; 2022 Jan; 49(1):647-656. PubMed ID: 34648139
[TBL] [Abstract][Full Text] [Related]
14. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
[TBL] [Abstract][Full Text] [Related]
15. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
16. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme.
Esparza TJ; Martin NP; Anderson GP; Goldman ER; Brody DL
Sci Rep; 2020 Dec; 10(1):22370. PubMed ID: 33353972
[TBL] [Abstract][Full Text] [Related]
17. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
18. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
Front Immunol; 2022; 13():820336. PubMed ID: 35663966
[TBL] [Abstract][Full Text] [Related]
19. Structure and function analysis of a potent human neutralizing antibody CA521
Song D; Wang W; Dong C; Ning Z; Liu X; Liu C; Du G; Sha C; Wang K; Lu J; Sun B; Zhao Y; Wang Q; Xu H; Li Y; Shen Z; Jiao J; Wang R; Tian J; Liu W; Wang L; Deng YQ; Dou C
Commun Biol; 2021 Apr; 4(1):500. PubMed ID: 33893388
[TBL] [Abstract][Full Text] [Related]
20. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
